Stockreport

Why Biohaven (BHVN) Is Down 52.0% After FDA Setback Forces R&D Overhaul [Yahoo! Finance]

Biohaven Pharmaceutical Holding Company Ltd. Common Shares  (BHVN) 
Last biohaven pharmaceutical holding company ltd. common shares earnings: 2/25 04:45 pm Check Earnings Report
US:NYSE Investor Relations: investors.biohavenpharma.com
PDF VYGLXIA (troriluzole) for spinocerebellar ataxia, prompting the company to restructure operations and R&D priorities. This regulatory setback marks a shift in Biohaven [Read more]